JCO oncology practice最新文献

{"title":"Ensuring Representation: A Scoping Review of Interventions to Increase Minority Participation in Cancer-Related Research.","authors":"David Lewis Pottinger, Soumya Niranjan, Nusrat Jahan, Aakash Desai","doi":"10.1200/OP-24-00468","DOIUrl":"https://doi.org/10.1200/OP-24-00468","url":null,"abstract":"<p><strong>Purpose: </strong>Minority representation in cancer-related clinical trials (CCTs) is often inadequate. This poses a threat to the generalizability of studies and risks promoting health inequities. This scoping review set out to examine strategies to promote minority participation in CCTs and across the entire continuity of cancer-related care.</p><p><strong>Methods: </strong>We reviewed articles in the following databases: EMBASE, Scopus, and PubMed. For inclusion, studies were required to focus, to a significant extent, on interventions to increase minority enrollment/retention. They were also required to objectively report the strength of these interventions, and either compare them with a control, or with a different intervention attempted.</p><p><strong>Results: </strong>After initially identifying 817 articles, we reviewed 337 articles in their entirety, and found 37 that satisfied our full list of inclusion and exclusion criteria. Five general categories of interventions emerged in these studies. These included educational interventions (n = 17), patient navigation (n = 12), community engagement (n = 8), autonomous recruitment strategies (n = 4), and financial assistance/incentives (n = 4). We then examined rates of statistical significance (for studies that assessed this). Seven of 10 articles that used education intervention strategies and assessed statistical significance demonstrated improvement in at least one variable. For patient navigation, 5/5 showed significance. For community engagement, 1/1 found a significant difference. For studies using an autonomous recruitment strategy, 2/2 showed an improvement. Finally, for financial assistance/incentives, 1/3 found a significant improvement in minority enrollment.</p><p><strong>Conclusion: </strong>Our study highlights the critical role of tailored educational interventions and patient navigation in increasing minority participation in cancer-related clinical trials. However, all five categories of interventions showed promise. More research is needed, particularly in assessing the efficacy of multipronged approaches, to ensure adequate minority participation in CCTs.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400468"},"PeriodicalIF":4.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence in Oncology: Fulfilling Its Promise While Avoiding Its Peril.","authors":"Chirag Shah, Stephen M Karlovits","doi":"10.1200/OP-25-00079","DOIUrl":"https://doi.org/10.1200/OP-25-00079","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500079"},"PeriodicalIF":4.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative Supportive Care Interventions in Older Adults With Cancer: Opportunities and Challenges.","authors":"Ying Wang, Fergal Fleming, Kah Poh Loh","doi":"10.1200/OP-25-00032","DOIUrl":"https://doi.org/10.1200/OP-25-00032","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500032"},"PeriodicalIF":4.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract Thinking and Statins With Immune Checkpoint Inhibitors: Enough to Change Clinical Practice?","authors":"Derek Raghavan, James Symanowski","doi":"10.1200/OP-25-00117","DOIUrl":"https://doi.org/10.1200/OP-25-00117","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500117"},"PeriodicalIF":4.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What's in the Syringe-Or Isn't: Defining Perioperative Supportive Care Interventions for Improved Surgical Outcomes Among Older Adults With Cancer.","authors":"Ana Berlin","doi":"10.1200/OP-25-00072","DOIUrl":"https://doi.org/10.1200/OP-25-00072","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500072"},"PeriodicalIF":4.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights.","authors":"Hedy L Kindler, Ibiayi Dagogo-Jack, Marc de Perrot, Michael W Drazer, Nofisat Ismaila, Raffit Hassan","doi":"10.1200/OP-25-00035","DOIUrl":"https://doi.org/10.1200/OP-25-00035","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500035"},"PeriodicalIF":4.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-Related Quality of Life for Persons Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (AMC-A01).","authors":"Thomas M Atkinson, Madhu Mazumdar, Grace Van Hyfte, Jeannette Y Lee, Yuelin Li, Kathleen A Lynch, Andrew Webb, Susan M Holland, Erica I Lubetkin, Stephen Goldstone, Mark H Einstein, Elizabeth A Stier, Dorothy J Wiley, Ronald Mitsuyasu, Isabella Rosa-Cunha, David M Aboulafia, Shireesha Dhanireddy, Jeffrey T Schouten, Rebecca Levine, Edward M Gardner, Hillary Dunlevy, Luis F Barroso, Gary Bucher, Jessica Korman, Benjamin Stearn, Timothy J Wilkin, Grant Ellsworth, Julia C Pugliese, David Cella, J Michael Berry-Lawhorn, Joel M Palefsky","doi":"10.1200/OP-24-00830","DOIUrl":"10.1200/OP-24-00830","url":null,"abstract":"<p><strong>Purpose: </strong>The Anal Cancer/High-grade squamous intraepithelial lesions Outcomes Research (ANCHOR) trial demonstrated that treating precancerous anal HSIL reduces the incidence of anal cancer by 57% in people with HIV. It remains unclear how HSIL treatment or monitoring without treatment affects patient-reported health-related quality of life (HRQoL). We evaluated differences in HRQoL for individuals who were randomly assigned to active monitoring (AM) or treatment for anal HSIL.</p><p><strong>Methods: </strong>Using an index designed and validated for use in ANCHOR, HRQoL was assessed before random assignment (T1), 2-7 days (+3 days) after random assignment/treatment (T2), and 28 days (±7 days) after random assignment/treatment (T3).</p><p><strong>Results: </strong>ANCHOR participants living with HIV (N = 124; mean [standard deviation, SD] age, 52.6 years [10.3]; n = 101 [81.5%] men; n = 65 [52.4%] White; n = 95 [76.6%] non-Hispanic; treatment n = 70 [56.4%]; and AM n = 54 [43.6%]) were included. Treatment arm participants had significant mean worsening from T1-T2 in physical symptoms (mean [SD] difference, 0.31 [0.51]; <i>P</i> = .0001) and impact on psychological functioning (mean [SD] difference, 0.25 [0.64]; <i>P</i> = .022) that significantly improved to T1 levels from T2-T3 (ie, mean [SD] difference, -0.25 [0.52]; <i>P</i> = .003; and mean [SD] difference, -0.07 [0.23]; <i>P</i> = .039, respectively). AM arm participants experienced significant mean improvement in impact on psychological functioning from T1-T3 (mean [SD], difference, -0.20 [0.50]; <i>P</i> = .017). After adjusting for T1, treatment arm participants had a larger mean improvement than AM arm participants in physical symptoms from T2-T3 (mean [SD] difference, -0.25 [0.52]; <i>P</i> = .024); no between-arm differences were observed for impact on physical or psychological functioning.</p><p><strong>Conclusion: </strong>Treatment arm participants experienced significant worsening in physical symptoms and impact on psychological functioning from T1-T2 but returned to prerandomization levels by T3, indicating that any immediate anal HSIL treatment-related impacts to HRQoL are temporary. Further research is needed to determine long-term impacts of anal HSIL treatment on HRQoL.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400830"},"PeriodicalIF":4.7,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Developments in the Management of Renal Cell Cancer.","authors":"Yu-Wei Chen, Justine Panian, Brent Rose, Aditya Bagrodia, Rana R McKay","doi":"10.1200/OP-24-00875","DOIUrl":"https://doi.org/10.1200/OP-24-00875","url":null,"abstract":"<p><p>The management of renal cell carcinoma (RCC) has seen significant advancements in recent years with the introduction of novel therapeutic agents and combination regimens. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape, particularly for advanced and metastatic RCC, where ICI-based combinations have shown substantial improvements in survival outcomes. Dual immunotherapy combinations, such as nivolumab plus ipilimumab, and ICI-vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) combinations, including pembrolizumab with axitinib, nivolumab with cabozantinib, and pembrolizumab with lenvatinib, have demonstrated overall survival (OS) benefits in first-line treatment, redefining the standard of care for advanced RCC. Adjuvant pembrolizumab is also approved for resected high-risk RCC and is the only adjuvant therapy that prolongs the OS in RCC. Additionally, the development of belzutifan, a hypoxia-inducible factor-2 alpha inhibitor, offers a new treatment option for patients whose disease progresses after ICI and VEGF TKI therapies. Recent results from CONTACT-3 and TiNiVo-2 confirm that ICI rechallenge should be generally discouraged. This review provides a detailed overview of the current evidence supporting immune-based combinations and novel agents such as belzutifan, as well as insights into treatment sequencing strategies for RCC.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400875"},"PeriodicalIF":4.7,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Participation in Electronic Patient-Reported Outcome Measures Collection as a Part of Routine Supportive Care Delivery in Oncology.","authors":"SriVarsha Katoju, Oliver T Nguyen, Sahana Rajasekhara, Young-Rock Hong, Amir Alishahi Tabriz, Kea Turner","doi":"10.1200/OP-24-00760","DOIUrl":"https://doi.org/10.1200/OP-24-00760","url":null,"abstract":"<p><strong>Purpose: </strong>The use of electronic patient-reported outcome measures (ePROMs) in supportive cancer care can lead to benefits, such as identifying at-risk patients in need of closer monitoring and treatment. Despite these benefits, most studies examining ePROMs in this area were for clinical trials rather than standard care. Since there is a need to identify which patients are more likely to participate in ePROMs, this study assessed ePROM participation rates and factors influencing greater participation among patients receiving supportive care.</p><p><strong>Methods: </strong>This retrospective data analysis took place at a supportive care clinic within a National Cancer Institute-designated Comprehensive Cancer Center in the southeastern United States. Starting in 2017, ePROM assessments were implemented using tablets for in-person appointments at the clinic. The assessments included the Patient Health Questionnaire-9, National Comprehensive Cancer Network Distress Thermometer, and Edmonton Symptom Assessment System with additional questions added for other symptoms. Logistic regression and zero-truncated negative binomial regression models were used to analyze factors associated with ePROM assessment submission.</p><p><strong>Results: </strong>The study included 4,780 patients, with 42.7% submitting at least one ePROM assessment. Higher odds of ePROM submission were observed among patients age 35-64 years, had Medicare, had nonmetastatic cancer, or had genitourinary, breast, or multiple cancers. Additionally, higher rates of ePROM submissions were observed among patients who were younger; had GI, breast, or multiple cancers; had nonmetastatic cancer; or had private insurance.</p><p><strong>Conclusion: </strong>This study reveals that submission rates of ePROM assessments in a cancer center's supportive care clinic may be influenced by patient demographics, cancer history, and social determinants of health. Interventions to improve ePROM submission rates may need to be tailored on the basis of cancer site, presence of metastatic cancer, and caregiver support.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400760"},"PeriodicalIF":4.7,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer-Related Cognitive Impairment: A Practical Guide for Oncologists.","authors":"Yu Zhang, Shelli R Kesler, Jorg Dietrich, Herta H Chao","doi":"10.1200/OP-24-00953","DOIUrl":"10.1200/OP-24-00953","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400953"},"PeriodicalIF":4.7,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}